All In Biotech

Drug Trial Radar · NCT00004650

Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss

Last checked: Nov 20, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Aug 1993

Primary completion

Not stated

Sponsor

Sponsor type
NIH
Collaborators
Washington University School of Medicine
First posted
Feb 25, 2000

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

OBJECTIVES: I. Quantify periodontal alveolar bone loss rates in postmenopausal women. II. Evaluate the effects of estrogen on alveolar bone loss rates in these patients. III. Determine whether changes in periodontal bone mass relate to bone mass changes in other skeletal sites in these patients.

Conditions

  • Osteoporosis

Interventions

  • conjugated estrogensDrug

  • MedroxyprogesteroneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.